抗凝药物的实验室监测  

Laboratory monitoring of the anticoagulant drugs

作　　者：张鸿艳[1] 任静[1] 门剑龙[1] Zhang Hongyan;Ren Jing;Men Jianlong(Precision Medicine Center,Tianjin Medical University General Hospital,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院精准医学中心

出　　处：《中国心血管杂志》2019年第6期565-570,共6页Chinese Journal of Cardiovascular Medicine

摘　　要：抗凝药物可分为口服抗凝药和胃肠外抗凝药,前者包括维生素K拮抗剂和非维生素K拮抗口服抗凝药,后者包括肝素类药物、比伐芦定和阿加曲班等。实验室监测有助于提高抗凝治疗的有效性和安全性,但需明确三个问题:哪些患者需要进行监测?哪些实验可用于监测?如何理解监测数据?Anticoagulant drugs could be divided into oral anticoagulants and parenteral anticoagulants,the oral anticoagulants include the vitamin K antagonists and non-vitamin K antagonist oral anticoagulants;the parenteral anticoagulants include heparin drugs,bivalirudin and agartroban.Laboratory monitoring could help to improve the effectiveness and safety of anticoagulant therapy,but three questions need to be clarified:Which patients need to be monitored?Which experiments could be used for monitoring?How to understand monitoring data?

关 键 词：抗凝药 血栓形成 出血 药物监测 

分 类 号：R54[医药卫生—心血管疾病]